Analysts Anticipate Heat Biologics Inc (NASDAQ:HTBX) Will Post Quarterly Sales of $910,000.00

Analysts expect that Heat Biologics Inc (NASDAQ:HTBX) will report sales of $910,000.00 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Heat Biologics’ earnings. The highest sales estimate is $1.10 million and the lowest is $730,000.00. Heat Biologics reported sales of $1.84 million during the same quarter last year, which indicates a negative year-over-year growth rate of 50.5%. The firm is scheduled to announce its next earnings report on Thursday, November 21st.

On average, analysts expect that Heat Biologics will report full year sales of $3.05 million for the current fiscal year, with estimates ranging from $2.89 million to $3.20 million. For the next fiscal year, analysts anticipate that the business will post sales of $2.80 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Heat Biologics.

Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. The company had revenue of $0.34 million during the quarter, compared to analyst estimates of $0.91 million. Heat Biologics had a negative return on equity of 75.51% and a negative net margin of 386.16%.

Separately, Brookline Capital Management initiated coverage on Heat Biologics in a research report on Monday, July 29th. They issued a “buy” rating and a $8.00 price objective for the company.

A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. grew its position in shares of Heat Biologics Inc (NASDAQ:HTBX) by 6.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,327,660 shares of the biopharmaceutical company’s stock after purchasing an additional 84,400 shares during the period. Vanguard Group Inc. owned approximately 3.90% of Heat Biologics worth $909,000 as of its most recent SEC filing. 5.55% of the stock is currently owned by institutional investors and hedge funds.

Heat Biologics stock traded up $0.01 during mid-day trading on Friday, hitting $0.39. The company’s stock had a trading volume of 89,401 shares, compared to its average volume of 119,371. The firm has a market capitalization of $13.40 million, a PE ratio of -0.44 and a beta of 1.76. Heat Biologics has a 1 year low of $0.35 and a 1 year high of $2.10. The company has a current ratio of 4.50, a quick ratio of 4.50 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $0.51 and its two-hundred day moving average is $0.74.

About Heat Biologics

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

See Also: Trading on Margin

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit